Sarah Herterich
YOU?
Author Swipe
View article: Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 1 shows healthy tissue expression of NaPi2b
View article: Supplementary Figure 4 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 4 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 4 shows no binding of NaPi2b mAb and TUB-040 ADC to NaPi2a and NaPi2c
View article: Supplementary Figure 3 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 3 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 3 shows high-affinity binding of NaPi2b mAb and TUB-040 ADC to HCC-78 cells
View article: Supplementary Table 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Table 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Table 2 shows toxicokinetic parameters of TUB-040 in rats
View article: Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 10 shows that TUB-040 does not induce lung toxicity in rats
View article: Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 7 shows absent cytotoxic activity of TUB-040 on target-negative primary human cells
View article: Supplementary Figure 6 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 6 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 6 shows strong cytotoxic and bystander activity of TUB-040
View article: Supplementary Methods 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Methods 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Methods 1 includes descriptions about chemicals, LC/MS methods, sample preparation for MS, DARav determination, TUB-040 conjugation and free exatecan quantification
View article: Supplementary Figure 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 2 shows determination of DAR average of TUB-040
View article: Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 9 shows binding of TUB-040 to FcgRs
View article: Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 5 shows cross-reactivity of TUB-040 to cynomolgus and rat NaPi2b
View article: Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Table 1 shows binding affinities of NaPi2b mAb and TUB-040 ADC to NaPi2b
View article: Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
TUB-040 is a highly homogeneous and hydrophilic antibody–drug conjugate (ADC) targeting sodium-dependent phosphate transport protein 2b (NaPi2b), a surface receptor overexpressed in ovarian cancer and non–small cell lung adenocarcinoma. Pr…
View article: Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
Supplementary Figure 8 shows mode of action of TUB-040
View article: OC39 - Exploring tumor-associated macrophages (TAM) polarisation in adrenocortical adenomas
OC39 - Exploring tumor-associated macrophages (TAM) polarisation in adrenocortical adenomas Open
Background/Introduction Macrophages polarisation toward M2 has been described in normal adrenal gland (NAG) and adrenocortical carcinoma (ACA), however their role in ACA remains poorly characterized. Purpose To characterize tumor-associate…
View article: TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile Open
TUB-040 is a highly homogeneous and hydrophilic antibody–drug conjugate (ADC) targeting sodium-dependent phosphate transport protein 2b (NaPi2b), a surface receptor overexpressed in ovarian cancer and non–small cell lung adenocarcinoma. Pr…
View article: Expanding the payload scope in antibody-drug conjugates: Unprecedented delivery of hydroxy-containing drugs through self-immolative phosphoramidates
Expanding the payload scope in antibody-drug conjugates: Unprecedented delivery of hydroxy-containing drugs through self-immolative phosphoramidates Open
Despite recent advances in targeted drug delivery, approved Antibody-Drug-Conjugates (ADCs) are still limited by the delivery of a restricted set of payloads with limited modes of action (MOA). Versatile linkers, applicable to functional g…
View article: Supplementary figure 1 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 1 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Dose-response curves for the ADC synthesized from trastuzumab and LP1 and LP3-LP3 on SKBR-3, HCC-78 and MDA-MB-468
View article: Supplementary figure 7 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 7 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Exatecan, DXd, Enhertu and trastuzumab-LP5 induce immunogenic cell death. Immunogenic cell death induced by exatecan, DXd, trastuzumab-LP5 DAR 8 and Enhertu. HER2-positive SKBR-3 and N-87 cells were treated for indicated time points with 2…
View article: Supplementary figure 6 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 6 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Exatecan, DXd, Enhertu and trastuzumab-LP5 induce S phase and G2/M arrest. Cell cycle arrest induced by exatecan, DXd, trastuzumab-LP5 DAR 8 and Enhertu. HER2-positive cells were treated for indicated time points and concentrations of resp…
View article: Data from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Data from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Topoisomerase I (TOP1) Inhibitors constitute an emerging payload class to engineer antibody–drug conjugates (ADC) as next-generation biopharmaceutical for cancer treatment. Existing ADCs are using camptothecin payloads with lower potency a…
View article: Supplementary figure 3 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 3 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Hydrophobic interaction chromatography measurements. Comparison of trastuzumab, trastuzumab-LP3 DAR8, trastuzumab-LP5 DAR8, Adcetris and Enhertu. Shown are chromatograms of Adcetris in black (Homogenous ADC, brentuximab conjugated to MC-VC…
View article: Supplementary figure 2 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 2 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Analytical SEC chromatograms of trastuzumab-LP3 DAR8, trastuzumab-LP5 DAR8 and Enhertu at day 0 and after storage for four weeks at 4°C and 37°C in the dark.
View article: Supplementary figure 5 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 5 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Enhertu and trastuzumab-LP5 induce DNA damage. DNA damage induced by exatecan, DXd, trastuzumab-LP5 DAR 8 and Enhertu. HER2-positive SKBR-3 cells were treated for indicated time points with 5 µg/ml respective ADCs. Cells were stained with …
View article: Organic synthesis from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Organic synthesis from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Organic Synthesis procedures for the linker payloads and characterization of products and intermediates.
View article: Supplementary figure 3 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 3 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Hydrophobic interaction chromatography measurements. Comparison of trastuzumab, trastuzumab-LP3 DAR8, trastuzumab-LP5 DAR8, Adcetris and Enhertu. Shown are chromatograms of Adcetris in black (Homogenous ADC, brentuximab conjugated to MC-VC…
View article: Supplementary figure 7 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 7 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Exatecan, DXd, Enhertu and trastuzumab-LP5 induce immunogenic cell death. Immunogenic cell death induced by exatecan, DXd, trastuzumab-LP5 DAR 8 and Enhertu. HER2-positive SKBR-3 and N-87 cells were treated for indicated time points with 2…
View article: ADC characterization from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
ADC characterization from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Characterization Data on the antibodies and antibody-drug-conjugates.
View article: Additional experimental procedures from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Additional experimental procedures from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
General information on the experiments and additional experimental procedures.
View article: Supplementary figure 5 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Supplementary figure 5 from Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates Open
Enhertu and trastuzumab-LP5 induce DNA damage. DNA damage induced by exatecan, DXd, trastuzumab-LP5 DAR 8 and Enhertu. HER2-positive SKBR-3 cells were treated for indicated time points with 5 µg/ml respective ADCs. Cells were stained with …